Literature DB >> 11700880

Negative-Pressure monitoring of tuberculosis isolation rooms within New York State hospitals.

N Pavelchak1, K Cummings, R Stricof, E Marshall, M Oxtoby, M London.   

Abstract

A previously published study recommended the daily use of visible smoke to test for negative air pressure in isolation rooms occupied by potentially infectious tuberculosis cases. Continuous monitoring devices were found to have poor reliability. Findings from our survey of engineering controls in acute-care hospitals within New York State support this recommendation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11700880     DOI: 10.1086/501943

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

Review 1.  Ventilation control for airborne transmission of human exhaled bio-aerosols in buildings.

Authors:  Hua Qian; Xiaohong Zheng
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Are positive-pressure ventilation lobby rooms effective for protective and source isolation?

Authors:  T T Poovelikunnel; A Barakat; A O'Hara; H J Humphreys; V Newmann; A F Talento
Journal:  J Hosp Infect       Date:  2020-06-08       Impact factor: 3.926

3.  Management of patients infected with airborne-spread diseases: an algorithm for infection control professionals.

Authors:  Terri Rebmann
Journal:  Am J Infect Control       Date:  2005-12       Impact factor: 2.918

4.  Improving natural ventilation in hospital waiting and consulting rooms to reduce nosocomial tuberculosis transmission risk in a low resource setting.

Authors:  A Roderick Escombe; Eduardo Ticona; Víctor Chávez-Pérez; Manuel Espinoza; David A J Moore
Journal:  BMC Infect Dis       Date:  2019-01-25       Impact factor: 3.090

5.  Hospital and community acquired infection and the built environment--design and testing of infection control rooms.

Authors:  J T Walker; P Hoffman; A M Bennett; M C Vos; M Thomas; N Tomlinson
Journal:  J Hosp Infect       Date:  2007-06       Impact factor: 3.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.